A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
Public ClinicalTrials.gov record NCT03164057. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
Study identification
- NCT ID
- NCT03164057
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Enrollment
- 206 participants
Conditions and interventions
Conditions
Interventions
- Asparaginase Erwinia Chrysanthemi, Recombinant-Rywn Drug
- Azacitidine Drug
- Cytarabine Drug
- Daunorubicin Drug
- Decitabine Drug
- Dexrazoxane Drug
- Erwinia asparaginase Drug
- Etoposide Drug
- Fludarabine Drug
- G-CSF Drug
- ITMHA Combination Product
- Idarubicin Drug
- Mitoxantrone Drug
- Sorafenib Drug
- Stem Cell Transplant Biological
Drug · Combination Product · Biological
Eligibility (public fields only)
- Age range
- 29 Days to 21 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 14, 2017
- Primary completion
- Sep 19, 2025
- Completion
- May 31, 2027
- Last update posted
- Apr 22, 2026
2017 – 2027
United States locations
- U.S. sites
- 10
- U.S. states
- 7
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Children's Hospital of Central California | Madera | California | 93636 | — |
| Children's Hospital of Orange County | Orange | California | 92968 | — |
| Lucile Packard Children's Hospital Stanford University | Palo Alto | California | 94304 | — |
| Rady Children's Hospital and Health Center | San Diego | California | 92123 | — |
| University of Chicago Children's Hospital (Comer) | Chicago | Illinois | 60637 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Children's Hospital of Michigan | Detroit | Michigan | 48201 | — |
| Sanford Children's Specialty Clinic | Sioux Falls | South Dakota | 57117 | — |
| St. Jude Children's Research Hospital | Memphis | Tennessee | 38105 | — |
| Cook Children's Medical Center | Fort Worth | Texas | 76104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03164057, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 22, 2026 · Synced May 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03164057 live on ClinicalTrials.gov.